Synthetic cannabinoids are laboratory made chemicals sprayed onto shredded plant material or dissolved into vape liquid, and sold under names such as Spice and K2. They are not cannabis and they are not a cheaper version of it. Where THC acts as a partial agonist at the CB1 receptor, synthetic cannabinoids may act as full agonists with higher potency, which is the pharmacological reason they send people to emergency departments at a far higher rate than cannabis does.
Last updated:
Key takeaways
- The name is misleading. These are not synthetic versions of THC, they are a large and shifting family of unrelated molecules that happen to bind the same receptor.
- THC is a partial agonist at CB1 and CB2. Many synthetic cannabinoids are full agonists with higher potency, and their metabolites bind more strongly still, which is thought to drive the greater toxicity.
- One review put the risk of an emergency room visit at roughly 30 times higher than with cannabis, with agitation 3.8 times and cardiotoxicity 9.2 times more likely.
- Part of the appeal is that they are mostly missed by routine urine drug screens, which is also why users have no idea what they have taken.
- South African law already draws the line by route, not by molecule: possession is lawful for a patient who obtained the substance from a practitioner or on prescription and uses it under that practitioner care.
What synthetic cannabinoids actually are
The United States National Institute on Drug Abuse describes them as a class of lab made substances that are chemically similar to chemicals found in the cannabis plant, though they often produce very different effects. Illicitly manufactured versions are typically added to liquid cartridges for vaping devices, or sprayed onto dried, shredded plant material so they can be smoked. The products are sometimes known as K2 and Spice.
The United Nations Office on Drugs and Crime files them under new psychoactive substances, defined as substances of abuse not controlled by the 1961 Single Convention on Narcotic Drugs or the 1971 Convention on Psychotropic Substances, but which may pose a public health threat. Within that system the UNODC effect group is named precisely: synthetic cannabinoid receptor agonists. That phrase is the whole story in three words. What unites these chemicals is not that they resemble cannabis, but that they switch on the same receptor.
The scale is not marginal. Up to October 2025, 153 countries and territories had reported one or more new psychoactive substances to the UNODC Early Warning Advisory.
Why synthetic cannabinoids are not a form of cannabis
This is the part that the packaging works hardest to obscure, and it is a genuine pharmacological difference rather than a matter of opinion.
A receptor agonist can be partial or full. A partial agonist produces a submaximal response no matter how much of it arrives, so the effect has a built in ceiling. A full agonist has no such ceiling. A 2019 review in The Mental Health Clinician states the position plainly: tetrahydrocannabinol displays partial agonism at the CB1 and CB2 receptors, whereas synthetic cannabinoids may be full agonists at those receptors. The same review notes that many of these compounds bind the receptors more tightly than THC does, and that their metabolites bind more strongly again, which may explain their greater potency and longer duration.
Remove the ceiling and the consequences follow. The same review reports that, on one analysis, the risk of an emergency room visit is approximately 30 times higher with synthetic cannabinoids than with cannabis, and that agitation and cardiotoxicity are respectively 3.8 and 9.2 times more likely.
So the street logic that a synthetic is simply strong cannabis is not merely wrong by degree. The two behave differently at the receptor, and one of them has no upper limit.
| Prescribed cannabis medicine | Synthetic cannabinoid product | |
|---|---|---|
| Active compound | Named cannabinoids, quantified on the label | Unknown and changeable, often not disclosed at all |
| Receptor behaviour | THC is a partial agonist, with a ceiling on effect | Frequently a full agonist, with no such ceiling |
| Consistency | Batch tested, so one dose resembles the next | Sprayed unevenly, so the same packet can vary within itself |
| Oversight | Prescriber, regulator and licensed pharmacy | None |
| If something goes wrong | A named product and a clinical record to work from | Nobody, including the treating clinician, knows what was taken |
The drug test myth that drives the market
NIDA records that people have reported using these products because they were sometimes cheaper and more accessible alternatives to cannabis, and are mostly undetected by routine urine drug screens. That single fact explains a great deal of the demand, particularly in workplaces and institutions that test.
It is worth seeing the trap in it. A standard immunoassay screens for THC metabolites. A synthetic cannabinoid is a structurally different molecule, so the screen has nothing to find. The user reads that as safety. What it actually means is that the substance in their body is one that neither the test, nor the seller, nor the doctor treating them can identify. If your interest is in how cannabis itself behaves on a test, we covered that separately in how long dagga stays in your system.
The same evasion drives the chemistry. Manufacturers alter the molecular scaffold to stay ahead of the schedules, which is why the family keeps growing and why each new compound arrives with no human safety data whatsoever.
Before you start
In South Africa, medical cannabis containing THC is prescription only through a registered doctor, usually via a SAHPRA Section 21 authorisation. This page is general information for adults 18 and over and is not medical advice. If someone has taken an unknown substance and is agitated, confused, having chest pain, seizures or difficulty breathing, get emergency medical help immediately rather than waiting to see if it passes. Tell the treating staff what was taken and hand over the packaging if you have it.
What South African law says
South Africa regulates this through two statutes that work together. Section 2 of the Drugs and Drug Trafficking Act 140 of 1992 states that its provisions apply in addition to, and not in substitution for, the Medicines Act. So a substance can be caught by both.
The Drugs and Drug Trafficking Act sorts substances into Schedule 2, whose parts define a dependence producing substance, a dangerous dependence producing substance and an undesirable dependence producing substance. Section 4 then prohibits use and possession of those substances, with a carefully drawn exemption. A patient is outside the prohibition where they acquired the substance from a medical practitioner, dentist or practitioner acting in a professional capacity under the Medicines Act, or from a pharmacist on that practitioner oral instruction or written prescription, and where they use it for medicinal purposes under that practitioner care.
Read that exemption closely, because it is the whole distinction. It does not turn on whether a molecule is natural or synthetic, or on how strong it is. It turns on the route: a practitioner, a prescription, and ongoing clinical care. A product bought from a stranger or a social media account cannot satisfy any of the three, whatever is in it.
The medicines side runs in parallel. Following the regulator communication on the scheduling status of THC and CBD, THC sits in Schedule 6 with narrow exceptions and CBD in Schedule 4 apart from defined low dose exceptions that fall to Schedule 0, and access to an unregistered cannabis medicine runs through a Section 21 authorisation applied for by the prescriber. Terms such as licence and permit get thrown around loosely in this area, and we untangled that language in dagga licence requirements. The consequences of getting the possession question wrong are set out in the penalty for possession of dagga in South Africa.
How to recognise a synthetic product
No one can identify a chemical by eye, and any guide that claims otherwise is overselling. What you can read reliably is the packaging and the sales pitch, because those follow a pattern.
- A brand name and a cartoon, with no named active ingredient and no quantity.
- The phrase not for human use printed on something plainly sold to be smoked or vaped. That wording exists to shift liability, and its presence is itself the warning.
- Category words that dodge the question: herbal incense, potpourri, aroma, botanical blend.
- Claims that the product is legal, herbal, or will not show on a test. A lawful cannabis medicine is never marketed on its ability to defeat a drug screen.
- A solvent or chemical smell, and plant matter that looks generic or unevenly darkened where it was sprayed.
- Vape cartridges with no cannabinoid figures and no laboratory report.
The useful contrast is with how a real cannabis product is described. A cultivar page such as Blue Zushi names the plant and its characteristics, and a dispensed medicine carries the cannabinoid content on the label. Absence of that information is not an oversight. It is the product.
If someone reacts badly
Severe reactions are documented across the literature and include marked agitation, psychosis, seizures, chest pain, cardiac events and deaths. There is no home remedy for any of that, and nothing on this page should be read as a reason to manage it yourself.
Get emergency medical help immediately if someone who has taken an unknown substance shows chest pain, seizures, breathing difficulty, loss of consciousness, uncontrolled agitation or confusion. Stay with them. Tell the clinicians exactly what you know, including that a product of unknown composition may be involved, and give them the packaging if it exists, because it can matter more to the treating team than anything the person can tell them. Clinicians treat the presentation rather than the molecule in these cases, which is precisely why the unknown composition makes the job harder.
If someone is using regularly, the route out is a clinician, not a different packet. Dependence and withdrawal are reported with these compounds, and that is a treatable medical issue rather than a matter of willpower.
How Professor Green fits into the process
Professor Green is a South African medical cannabis access platform and a marketing affiliate of the Dr Green network, which holds the medical cannabis licences in South Africa. Professor Green does not itself sell, handle or ship cannabis. Products are sold and fulfilled by the licensed operator.
Professor Green has no involvement with synthetic cannabinoids of any kind, and no lawful South African supply route does. The reason this article sits on this site is narrower than a sales pitch: a good part of the demand for Spice and similar products comes from people who wanted cannabis for a health reason and believed the legal route was closed to them. It is not closed, although it is slower and it runs through a registered doctor rather than around one.
Registering with Professor Green creates an account and opens the member area so the process can begin. It does not make anyone eligible, does not issue a prescription, does not authorise anything under Section 21 and does not guarantee supply. A registered doctor assesses and prescribes, SAHPRA decides any Section 21 application, and a licensed pharmacy dispenses. If you want the documents side of that explained, see our guide to what stands in for a medical cannabis card in South Africa.
Frequently asked questions
Are Spice and K2 just strong cannabis?
No. They are unrelated laboratory made molecules that bind the same receptor. THC is a partial agonist at CB1 and CB2, so its effect has a ceiling, while these compounds may be full agonists with higher potency and no such ceiling.
Why do these products not show up on a drug test?
A routine urine screen looks for THC metabolites. These are structurally different molecules, so the screen has nothing to detect. That also means neither the user nor a treating clinician can tell what was actually taken.
Is a product legal just because it is sold openly?
No. Open sale is not a legal opinion. Under South African law, lawful patient possession depends on the route: a practitioner or pharmacist supplying on prescription, and use for medicinal purposes under that practitioner care.
What does not for human use mean on the packaging?
It is a liability disclaimer placed on a product that is plainly intended to be smoked or vaped. Treat its presence as a warning sign rather than as reassurance about the contents.
What should I do if someone has a severe reaction?
Get emergency medical help immediately for chest pain, seizures, breathing difficulty, loss of consciousness or uncontrolled agitation. Stay with the person, tell staff an unknown substance may be involved, and hand over the packaging if you have it.
Can these products cause dependence?
Dependence and withdrawal are reported with these compounds. It is a medical issue and a clinician is the right person to approach, rather than switching to a different unknown product.
What is the lawful route to cannabis medicine in South Africa?
A registered doctor assesses you and prescribes. Where the product is unregistered, the doctor applies to SAHPRA for a Section 21 authorisation. A licensed pharmacy then dispenses it. Registration with a platform is a first step, not an approval.
The bottom line on synthetic cannabinoids
Synthetic cannabinoids borrowed the word cannabis and almost none of its properties. They are a moving family of full agonist chemicals, made to stay ahead of drug schedules and drug tests, sold with no ingredient list to people who are told they are buying a legal version of something familiar. The pharmacology is different, the risk profile is worse by a wide margin, and the anonymity that makes them attractive is the same feature that makes a bad reaction so hard to treat. South African law, for its part, has never asked whether a molecule is natural. It asks who supplied it, on what authority, and whether a clinician is still involved. That is the only line worth standing on, and it is the one these products are built to avoid.
Looking into the legal route instead?
If you came here because you were weighing up an unregulated product against the prescribed one, you can explore how Professor Green works and start an account. Registering is a first step only. It is not an approval, a prescription or a guarantee of supply, and eligibility is decided by a registered doctor.
Create Your Professor Green AccountSources and references
- National Institute on Drug Abuse, Synthetic Cannabinoids (October 2023), for what these substances are, how they are prepared and sold, and their evasion of routine urine screens.
- UNODC Early Warning Advisory on New Psychoactive Substances, for the definition of a new psychoactive substance, the synthetic cannabinoid receptor agonist effect group, and the figure of 153 reporting countries and territories up to October 2025.
- Review of the many faces of synthetic cannabinoid toxicities, The Mental Health Clinician, 2019, for partial versus full agonism at CB1 and CB2 and the comparative emergency room, agitation and cardiotoxicity figures.
- Drugs and Drug Trafficking Act 140 of 1992, section 2 (operation alongside the Medicines Act) and section 4 (use and possession, and the patient exemption).
- SAHPRA communication to industry on the scheduling status of THC and CBD, for the Schedule 0, Schedule 4 and Schedule 6 positions.
- Medicines and Related Substances Act 101 of 1965, section 21, for the authorisation route to an unregistered medicine.
Last reviewed September 2026. Drug schedules and regulatory positions change; verify time sensitive points against the primary sources above before relying on them.

